

A study on macrolide and lincosamide resistance in pathogenic Gram positive cocci

Thesis

**Submitted in partial fulfillment for the requirements of the
Master degree of Science in Microbiology**

By

Doha Mohamed Ashour Mahmoud

(B.Sc. Microbiology/Chemistry, 2010)

Supervisors

Prof. Dr. Mohamed Khaled Ibrahim

Professor of Bacteriology

Vice dean of education and student affairs

Faculty of Science, Ain Shams University

Prof. Dr. Mona Mohiedden Abdelhalim

Professor of Clinical and Chemical Pathology

Clinical and Chemical Pathology Department

Faculty of Medicine, Cairo University

Dr. Sahar Tolba Mohamed

Assistant Professor of Microbiology

Microbiology Department

Faculty of Science, Ain Shams University

2017

A study on macrolide and lincosamide resistance in pathogenic Gram positive cocci

Thesis

**Submitted in partial fulfillment for the requirements of the
Master degree of Science in Microbiology**

By

Doha Mohamed Ashour Mahmoud

(B.Sc. Microbiology/Chemistry, 2010)

Department of Microbiology

Faculty of Science

Ain Shams University

2017

Acknowledgment

First of all, I would like to express my sincerest gratitude and thanks to Allah who gives me patience for any success in life.

I would like to express my sincere gratitude and appreciation to Prof. Dr. Mohamed Khaled Ibrahim, Professor of Bacteriology, Faculty of Science, Ain Shams University, for his supervision, continuous guidance and great support throughout this work.

My cardinal gratitude to Prof. Dr. Mona Mohiedden Abdelhalim, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, for her sincere guidance and great help in this work.

I am also profoundly grateful to Dr. Sahar Tolba Mohamed, Assistant Professor of Microbiology, Faculty of Science, Ain Shams University, for her sincere guidance, valuable advice and continuous encouragement in this work.

My deep thanks to Microbiology Department, Faculty of Science, Ain Shams University.

Special thanks to the microbiology laboratory of CUSPH for great help and support all over the practical steps of this work.

My deepest gratitude to my family, especially my mother for their support and encouragement throughout my life.

CONTENTS

Subjects	Page
List of tables	IV
List of figures	VI
Abbreviations	VIII
1. Introduction	1
2. Review of literature	3
2.1. Antibiotic resistance	3
2.2. Gram positive pathogenic cocci	6
2.2.1. <i>Staphylococcus sp.</i>	7
2.2.1.1. Classification of staphylococci	7
2.2.1.2. Characteristics of staphylococci	7
2.2.1.3. <i>Staphylococcus aureus</i>	8
2.2.1.3.1. Epidemiology	8
2.2.1.3.2. Virulence factors of <i>S. aureus</i> and pathogenesis	8
2.2.1.4. Coagulase negative staphylococci (CoNS)	11
2.2.1.4.1. Epidemiology	11
2.2.1.4.2. Virulence factors and disease	12
2.2.2. <i>Streptococcus sp.</i>	13
2.2.2.1. Classification of <i>Streptococcus</i>	13
2.2.2.2. Characteristics of <i>Streptococcus</i>	13
2.2.2.3. <i>Streptococcus pneumoniae</i>	13
2.2.2.3.1. Epidemiology	14
2.2.2.3.2. Virulence factors and disease	14
2.3. Antibiotic resistance in Gram positive pathogenic cocci	15
2.3.1. β -lactam antibiotics	15
2.3.1.1. Methicillin resistance	16
2.3.2. Glycopeptide antibiotics	17
2.3.2.1. Vancomycin resistance	17
2.3.3. Sulphonamides - Trimethoprim	18
2.3.3.1. Mechanism of resistance	19
2.3.4. Quinolones	20

2.3.4.1. Quinolone resistance	21
2.3.5. Aminoglycosides	22
2.3.5.1. Aminoglycoside resistance	23
2.3.6. Tetracyclines	23
2.3.6.1. Tetracycline resistance	24
2.4. Macrolide and lincosamide antibiotics	25
2.4.1. Chemical structure of macrolides and lincosamides	25
2.4.2. Mode of action of macrolides and lincosamides	28
2.4.3. Mechanism of action	29
2.4.4. Macrolide and lincosamide resistance	30
2.4.4.1. Target site modification by methylation or mutation	30
2.4.4.2. Efflux of the antibiotics	33
2.4.4.3. Drug inactivation	35
2.4.4.4. Transmission of resistance genes	36
2.4.4.5. Regulation of resistance genes	37
3. Materials & Methods	42
3.1. Clinical samples	42
3.2. Isolation of bacteria from clinical samples	42
3.3. Identification of bacterial isolates	42
3.3.1. Species identification of staphylococci	43
3.3.1.1. Coagulase production (Coagulase test)	43
3.3.1.2. Novobiocin resistance	43
3.3.1.3. Polymyxin B resistance	43
3.3.1.4. Ornithine decarboxylase activity (Ornithine decarboxylase test)	44
3.3.1.5. DNase test	44
3.3.1.6. Urease test	45
3.3.1.7. Mannitol fermentation (Acid production)	45
3.3.2. Species identification of streptococci	47
3.3.2.1. Hemolytic reaction	47
3.3.2.2. Optochin test	47
3.4. Media used in the study	47

3.5. Antibiotic susceptibility test	49
3.6. Determination of MLS_B resistance phenotypes (double disk diffusion – D zone test)	52
3.7. Determination of minimal inhibitory concentration (MIC test)	53
3.8. DNA extraction from bacteria	54
3.9. Polymerase Chain Reaction (PCR)	54
3.9.1. PCR primers	54
3.9.2. Multiplex PCR	54
3.9.2.1. Staphylococci	54
3.9.2.2. Streptococci	55
3.10. Electrophoresis of PCR product	55
3.10.1. Buffers and reagents and biochemicals	56
3.11. Statistics	58
4. Results	59
4.1. Collection of samples	59
4.2. Identification of bacterial isolates	59
4.3. Antibiotic susceptibility pattern	63
4.4. Macrolide lincosamide streptogramin B (MLS_B) resistance phenotype	67
4.5. The relation between methicillin resistance and susceptibility profile to erythromycin and clindamycin	70
4.6. Minimal inhibitory concentration (MIC)	72
4.7. Polymerase Chain Reaction (PCR)	74
4.8. Correlation between MLS_B resistance phenotype and genotype	79
5. Discussion	82
Summary	95
References	98
Arabic summary	

List of Tables

Subject	Page
Table (A): Selected <i>Staphylococcus aureus</i> virulence factors	10
Table (1): Key tests for identification of the most clinically significant <i>Staphylococcus</i> species	46
Table (2): Media used in isolation, identification, antibiotic susceptibility and MIC of the isolates	48
Table (3): Zone diameter ranges of each antibiotic used in this study for staphylococcal isolates	50
Table (4): Zone diameter ranges of each antibiotic used in the study for <i>Streptococcus pneumoniae</i> isolates	51
Table (5): MIC interpretive criteria	53
Table (6): Primers used in the multiplex PCR assay for the detection of macrolide resistance genes in staphylococcal isolates	57
Table (7): Primers used in the multiplex PCR assay for the detection of macrolide resistance genes in streptococcal isolates	57
Table (8): Distribution of identified Gram positive cocci isolates in this study	61
Table (9): Identification tests for <i>S. aureus</i> and CoNS	62
Table (10): Distribution of isolated species among different clinical samples	62
Table (11): Percentage of the susceptibility to various antibiotics used in the study among different species of <i>Staphylococcus</i>	66
Table (12): Percentage of the susceptibility to various antibiotics among <i>Streptococcus pneumoniae</i>	66

Table (13): MLS_B resistance phenotype designation among different species of <i>Staphylococcus</i> and <i>Streptococcus</i> spp.	68
Table (14): Susceptibility profile to erythromycin and clindamycin of susceptible and methicillin-resistant <i>S. aureus</i> and CoNS	71
Table (15): MIC for clindamycin and erythromycin of the selected staphylococcal and streptococcal isolates	72
Table (16): Distribution of the studied resistance genes among isolated staphylococci	74
Table (17): Distribution of the studied resistance genes among isolated <i>Str. pneumoniae</i>	74
Table (18): Distribution of the studied resistance genes among isolated CoNS	75
Table (19): Correlation between the studied resistance genes and MLS_B resistance phenotypes among staphylococcal species	80
Table (20): Correlation between the studied resistance genes and MLS_B resistance phenotypes among <i>Streptococcus pneumoniae</i>	81

List of Figures & Photos

Subject	Page
Figure (A): Acquisition of Antibiotic Resistance	5
Figure (B): Sulphonamides and trimethoprim inhibit distinct steps in folate metabolism	19
Figure (C): Chemical structure of erythromycin A	26
Figure (D): The chemical structure of clarithromycin, azithromycin, tylosin and telithromycin	27
Figure (E): Chemical structures of lincomycin and clindamycin	28
Figure (F): Translational attenuation of <i>ermC</i> gene expression	39
Figure (G): Transcriptional attenuation of <i>erm</i> (K)	41
Figure (1): Distribution of identified Gram positive cocci isolates in this study	61
Photo (2): Representative MIC test for vancomycin	63
Photo (3): Representative D-zone test for inducible clindamycin resistance	69
Figure (4): The percentage of the distribution of MLS_B resistance phenotypes between the isolates	69
Figure (5): The relation between MR and MLS_B phenotypes in the staphylococcal isolates	71
Photo (6): Representative MIC test. A: MIC for clindamycin and B: MIC for erythromycin	73
Photo (7): Representative MIC test for clindamycin	73
Figure (8): The distribution of resistance genes among <i>S. aureus</i> and CoNS	76
Figure (9): Frequency of resistance genes in <i>Streptococcus pneumoniae</i> isolates	77

Photo (10): PCR amplification of <i>ermC</i> gene (190bp). Lanes 1-8 are Staphylococci isolates showing positive <i>ermC</i>, L is 100 bp DNA ladder.	77
Photo (11): PCR amplification of <i>msrA</i> gene (163 bp). Lanes 1-10 are staphylococci isolates showing positive <i>msrA</i>, L is 100 bp DNA ladder.	78
Photo (12): PCR amplification of <i>ermA</i> (590bp), <i>mefA/E</i> (317bp). L is 100 bp DNA ladder.	78

List of Abbreviations

A: Adenine

AAC: Aminoglycoside acetyltransferases

ABC: ATP-binding cassette

Ab^r: Antibiotic resistant

ACME: Arginine catabolic mobile element

AIDS: Acquired immune deficiency syndrome

ANT: Aminoglycoside nucleotidyltransferases

APH: Aminoglycoside phosphotransferases

CA-MRSA: Community acquired methicillin resistant
Staphylococcus aureus

CD: Clindamycin

CDC: Centers for Disease Control and Prevention

Cfr: PhLOPSa resistance gene

CHIPS: Chemotaxis inhibitory protein of staphylococci

CIP: Ciprofloxacin

CLSI: Clinical and Laboratory Standards Institute

cMLS_B: Constitutive macrolide lincosamide streptogramin B
resistance phenotype

CoNS: Coagulase-negative staphylococci